Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 1;110(10):6432-6455.
doi: 10.1097/JS9.0000000000001892.

Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies

Popat Mohite  1 , Abhijeet Puri  1 , Roshan Dave  1 , Aarati Budar  1 , Shubham Munde  1 , Shruti Bagchi Ghosh  2 , Taha Alqahtani  3 , Humood Al Shmrany  4 , Ajoy Kumer  5 , Bikram Dhara  6   7
Affiliations
Review

Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies

Popat Mohite et al. Int J Surg. .

Abstract

This review explores the application of induced pluripotent stem cells (iPSCs) in regenerative medicine. The therapeutic significance of iPSC-derived cell therapy within regenerative medicine, emphasizes their reprogramming process and crucial role in cellular differentiation while setting the purpose and scope for the comprehensive exploration of iPSC-derived cell therapy. The subsequent sections intricately examine iPSC-derived cell therapy, unraveling the diverse derivatives of iPSCs and striking a delicate balance between advantages and limitations in therapeutic applications. Mechanisms of action, revealing how iPSC-derived cells seamlessly integrate into tissues, induce regeneration, and contribute to disease modeling and drug screening advancements is discussed. The analysis extends to clinical trials, shedding light on outcomes, safety considerations, and ethical dimensions. Challenges and concerns, including the risk of tumorigenesis and scalability issues, are explored. The focus extends to disease-specific applications, showcasing iPSC-derived cell therapy as a promising avenue for various medical conditions, supported by illustrative case studies. Future directions and research needs are outlined, identifying areas for further exploration, safety considerations and potential enhancements that will shape the future landscape of iPSC-derived therapies. In conclusion, this review provides a significant understanding of iPSC-derived cell therapy's status that contemplates the implications for regenerative medicine and personalized treatment using iPSCs, offering a comprehensive perspective on the evolving field within the confines of a dynamic and promising scientific frontier.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest exists.

Figures

None
Graphical abstract
Figure 1
Figure 1
iPSC derived stem cell therapy. iPSC, induced pluripotent stem cell.
Figure 2
Figure 2
Approaches for reprogramming somatic nuclei. iPSC, induced pluripotent stem cell; SCNT, somatic cell nuclear transfer.
Figure 3
Figure 3
Delivery methods of reprogramming factors.
Figure 4
Figure 4
Evaluating the most effective vaccination timetable, succeeded by the successful preventive treatment of breast cancer and melanoma in mice (adapted with permission under CCBY 4.0 from). iPSC, induced pluripotent stem cell.
Figure 5
Figure 5
Generation of iPSCs, Differentiation of iPSCs in vivo in vitro, Immunofluorescence staining of iPSCs (adapted with permission under CCBY 4.0 from). iPSC, induced pluripotent stem cell.
Figure 6
Figure 6
Characterization of iPSCs (adapted with permission under CCBY 4.0 from). iPSC, induced pluripotent stem cell.
Figure 7
Figure 7
iPSC derived exosomes for human heart diseases. iPSC, induced pluripotent stem cell.
Figure 8
Figure 8
Therapeutic potential of iPSC-derived exosomes for heart disease. iPSC, induced pluripotent stem cell.
Figure 9
Figure 9
iPSC-based cell therapy for diabetic wound treatment. iPSC, induced pluripotent stem cell.
Figure 10
Figure 10
iPSCs in autoimmune neurological disease—multiple sclerosis. iPSC, induced pluripotent stem cell.
Figure 11
Figure 11
iPSC-based therapeutics for multiple sclerosis. CNS, central nervous system; iPSC, induced pluripotent stem cell; MS, multiple sclerosis; NPC, neural precursor cell; OPC, Oligodendrocyte precursor cell.
Figure 12
Figure 12
Human iPSC application in Alzheimer’s disease and Tau-related neurodegenerative diseases. iPSC, induced pluripotent stem cell.
Figure 13
Figure 13
Contribution of iPSCs in Alzheimer’s disease. AD, Alzheimer’s disease; iPSC, induced pluripotent stem cell.
Figure 14
Figure 14
Induced pluripotent stem cell in tissue regeneration and repair. RBC, red blood cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009;87:2183–2200. - PubMed
    1. Shi Y, Inoue H, Wu JC, et al. . Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 2017;16:115–130. - PMC - PubMed
    1. Rehakova D, Souralova T, Koutna I. Clinical-grade human pluripotent stem cells for cell therapy: characterization strategy. Int J Mol Sci 2020;21:2435. - PMC - PubMed
    1. Okano H, Nakamura M, Yoshida K, et al. . Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 2013;112:523–533. - PubMed
    1. Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ 2018;6:e4370. - PMC - PubMed

MeSH terms

LinkOut - more resources